DNA methylation analyses of urothelial carcinoma reveal distinct epigenetic subtypes and an association between gene copy number and methylation status

Epigenetics

Volumn 7, Issue 8, 2012, Pages 858-867

  Lauss, Martin ^a   Aine, Mattias ^a   Sjödahl, Gottfrid ^a   Veerla, Srinivas ^a   Patschan, Oliver ^a   Gudjonsson, Sigurdur ^a   Chebil, Gunilla ^a   Lövgren, Kristina ^a   Fernö, Mårten ^a   Månsson, Wiking ^a   Liedberg, Fredrik ^a   Ringnér, Markus ^a   Lindgren, David ^a   Höglund, Mattias ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Bladder cancer; Copy number changes; DNA methylation; Gene expression; Molecular subtypes; Polycomb; Transcription factor

Indexed keywords

MESSENGER RNA; MYC PROTEIN; POLYCOMB GROUP PROTEIN;

ARTICLE; BINDING SITE; CANCER INVASION; CELL INFILTRATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CPG ISLAND; DNA METHYLATION; EPIGENETICS; FEMALE; GENE DOSAGE; GENE EXPRESSION; GENE IDENTIFICATION; GENE MUTATION; GENE SILENCING; GENETIC ASSOCIATION; HOX GENE; HUMAN; IMMUNOCOMPETENT CELL; MALE; TRANSITIONAL CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

EID: 84864701954     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.4161/epi.20837     Document Type: Article

References (50)

1. Avritscher EBC, Cooksley CD, Grossman HB, Sabichi AL, Hamblin L, Dinney CP, et al. Clinical model of lifetime cost of treating bladder cancer and associated complications. Urology 2006. 68:549-553. PMID:16979735. http://dx.doi.org/10.1016/j.urology.2006.03.062.
2. Sjödahl G, Lauss M, Gudjonsson S, Liedberg F, Halldén C, Chebil G, et al. A systematic study of gene mutations in urothelial carcinoma. inactivating mutations in TSC2 and PIK3R1. PLoS One 2011. 6:18583. PMID:21533174. http://dx.doi.org/10.1371/journal.pone.0018583.
3. Blaveri E, Brewer JL, Roydasgupta R, Fridlyand J, DeVries S, Koppie T, et al. Bladder cancer stage and outcome by array-based comparative genomic hybridization. Clin Cancer Res 2005. 11:7012-7022. PMID:16203795. http://dx.doi.org/10.1158/1078-0432.CCR-05-0177.
4. Blaveri E, Simko JP, Korkola JE, Brewer JL, Baehner F, Mehta K, et al. Bladder cancer outcome and subtype classification by gene expression. Clin Cancer Res 2005. 11:4044-4055. PMID:15930339. http://dx.doi.org/10.1158/1078-0432.CCR-04-2409.
5. Sanchez-Carbayo M, Socci ND, Lozano J, Saint F, Cordon-Cardo C. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol 2006. 24:778-789. PMID:16432078. http://dx.doi.org/10.1200/JCO.2005.03.2375.
6. Dyrskjøt L, Zieger K, Real FX, Malats N, Carrato A, Hurst C, et al. Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study. Clin Cancer Res 2007. 13:3545-3551. PMID:17575217. http://dx.doi.org/10.1158/1078-0432.CCR-06-2940.
7. Lindgren D, Frigyesi A, Gudjonsson S, Sjödahl G, Hallden C, Chebil G, et al. Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome. Cancer Res 2010. 70:3463-3472. PMID:20406976. http://dx.doi.org/10.1158/0008-5472.CAN-09-4213.
8. Esteller M. Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum Mol Genet 2007. 16:50-59. PMID:17613547. http://dx.doi.org/10.1093/hmg/ddm018.
9. Hansen KD, Timp W, Bravo HC, Sabunciyan S, Langmead B, McDonald OG, et al. Increased methylation variation in epigenetic domains across cancer types. Nat Genet 2011. 43:768-75. PMID:21706001. http://dx.doi.org/10.1038/ng.865.
10. Veerla S, Panagopoulos I, Jin Y, Lindgren D, Höglund M. Promoter analysis of epigenetically controlled genes in bladder cancer. Genes Chromosomes Cancer 2008. 47:368-378. PMID:18196590. http://dx.doi.org/10.1002/gcc.20542.
11. Weber M, Hellmann I, Stadler MB, Ramos L, Pääbo S, Rebhan M, et al. Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat Genet 2007. 39:457-466. PMID:17334365. http://dx.doi.org/10.1038/ng1990.
12. Holm K, Hegardt C, Staaf J, Vallon-Christersson J, Jönsson G, Olsson H, et al. Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns. Breast Cancer Res 2010. 12:36. PMID:20565864. http://dx.doi.org/10.1186/bcr2590.
13. Van der Auwera I, Yu W, Suo L, Van Neste L, van Dam P, Van Marck EA, et al. Array-based DNA methylation profiling for breast cancer subtype discrimination. PLoS One 2010. 5:12616. PMID:20830311. http://dx.doi.org/10.1371/journal.pone.0012616.
14. Fang F, Turcan S, Rimner A, Kaufman A, Giri D, Morris LGT, et al. Breast cancer methylomes establish an epigenomic foundation for metastasis. Sci Transl Med 2011. 3:75. PMID:21430268. http://dx.doi.org/10.1126/scitranslmed.3001875.
15. Hinoue T, Weisenberger DJ, Lange CPE, Shen H, Byun HM, Van Den Berg D, et al. Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res 2012. 22:271-282. PMID:21659424. http://dx.doi.org/10.1101/gr.117523.110.
16. Martin-Subero JI, Ammerpohl O, Bibikova M, Wickham-Garcia E, Agirre X, Alvarez S, et al. A comprehensive microarray-based DNA methylation study of 367 hematological neoplasms. PLoS One 2009. 4:6986. PMID:19750229. http://dx.doi.org/10.1371/journal.pone.0006986.
17. Stransky N, Vallot C, Reyal F, Bernard-Pierrot I, de Medina SGD, Segraves R, et al. Regional copy numberindependent deregulation of transcription in cancer. Nat Genet 2006. 38:1386-1396. PMID:17099711. http://dx.doi.org/10.1038/ng1923.
18. Vallot C, Stransky N, Bernard-Pierrot I, Hérault A, Zucman-Rossi J, Chapeaublanc E, et al. A novel epigenetic phenotype associated with the most aggressive pathway of bladder tumor progression. J Natl Cancer Inst 2011. 103:47-60. PMID:21173382. http://dx.doi.org/10.1093/jnci/djq470.
19. Wolff EM, Chihara Y, Pan F, Weisenberger DJ, Siegmund KD, Sugano K, et al. Unique DNA methylation patterns distinguish noninvasive and invasive urothelial cancers and establish an epigenetic field defect in premalignant tissue. Cancer Res 2010. 70:8169-8178. PMID:20841482. http://dx.doi.org/10.1158/0008-5472.CAN-10-1335.
20. Wilhelm-Benartzi CS, Koestler DC, Houseman EA, Christensen BC, Wiencke JK, Schned AR, et al. DNA methylation profiles delineate etiologic heterogeneity and clinically important subgroups of bladder cancer. Carcinogenesis 2010. 31:1972-1976. PMID:20802236. http://dx.doi.org/10.1093/carcin/bgq178.
21. Reinert T, Modin C, Castano FM, Lamy P, Wojdacz TK, Hansen LL, et al. Comprehensive genome methylation analysis in bladder cancer: identification and validation of novel methylated genes and application of these as urinary tumor markers. Clin Cancer Res 2011. 17:5582-5592. PMID:21788354. http://dx.doi.org/10.1158/1078-0432.CCR-10-2659.
22. Schlesinger Y, Straussman R, Keshet I, Farkash S, Hecht M, Zimmerman J, et al. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet 2007. 39:232-236. PMID:17200670. http://dx.doi.org/10.1038/ng1950.
23. Du P, Zhang X, Huang CC, Jafari N, Kibbe WA, Hou L, et al. Comparison of Beta-value and M-value methods for quantifying methylation levels by microarray analysis. BMC Bioinformatics 2010. 11:587. PMID:21118553. http://dx.doi.org/10.1186/1471-2105-11-587.
24. Teschendorff AE, Menon U, Gentry-Maharaj A, Ramus SJ, Weisenberger DJ, Shen H, et al. Agedependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer. Genome Res 2010. 20:440-446. PMID:20219944. http://dx.doi.org/10.1101/gr.103606.109.
25. Lee TI, Jenner RG, Boyer LA, Guenther MG, Levine SS, Kumar RM, et al. Control of developmental regulators by Polycomb in human embryonic stem cells. Cell 2006. 125:301-313. PMID:16630818. http://dx.doi.org/10.1016/j.cell.2006.02.043.
26. Heidenblad M, Lindgren D, Jonson T, Liedberg F, Veerla S, Chebil G, et al. Tiling resolution array CGH and high density expression profiling of urothelial carcinomas delineate genomic amplicons and candidate target genes specific for advanced tumors. BMC Med Genomics 2008. 1:3. PMID:18237450. http://dx.doi.org/10.1186/1755-8794-1-3.
27. Ball MP, Li JB, Gao Y, Lee JH, LeProust EM, Park IH, et al. Targeted and genome-scale strategies reveal gene-body methylation signatures in human cells. Nat Biotechnol 2009. 27:361-368. PMID:19329998. http://dx.doi.org/10.1038/nbt.1533.
28. James L, Eisenman RN. Myc and Mad bHLHZ domains possess identical DNA-binding specificities but only partially overlapping functions in vivo. Proc Natl Acad Sci USA 2002. 99:10429-10434. PMID:12149476. http://dx.doi.org/10.1073/pnas.162369299.
29. Perini G, Diolaiti D, Porro A, Della Valle G. In vivo transcriptional regulation of N-Myc target genes is controlled by E-box methylation. Proc Natl Acad Sci USA 2005. 102:12117-12122. PMID:16093321. http://dx.doi.org/10.1073/pnas.0409097102.
30. Fujii G, Nakamura Y, Tsukamoto D, Ito M, Shiba T, Takamatsu N. CpG methylation at the USF-binding site is important for the liver-specific transcription of the chipmunk HP-27 gene. Biochem J 2006. 395:203-209. PMID:16396632. http://dx.doi.org/10.1042/BJ20051802.
31. Qiao H, May JM. CpG methylation at the USFbinding site mediates cell-specific transcription of human ascorbate transporter SVCT2 exon 1a. Biochem J 2011. 440:73-84. PMID:21770893. http://dx.doi.org/10.1042/BJ20110392.
32. Rishi V, Bhattacharya P, Chatterjee R, Rozenberg J, Zhao J, Glass K, et al. CpG methylation of half-CRE sequences creates C/EBPalpha binding sites that activate some tissue-specific genes. Proc Natl Acad Sci USA 2010. 107:20311-20316. PMID:21059933. http://dx.doi.org/10.1073/pnas.1008688107.
33. Rössler J, Stolze I, Frede S, Freitag P, Schweigerer L, Havers W, et al. Hypoxia-induced erythropoietin expression in human neuroblastoma requires a methylation free HIF-1 binding site. J Cell Biochem 2004. 93:153-161. PMID:15352172. http://dx.doi.org/10.1002/jcb.20133.
34. Brenner C, Deplus R, Didelot C, Loriot A, Viré E, De Smet C, et al. Myc represses transcription through recruitment of DNA methyltransferase corepressor. EMBO J 2005. 24:336-346. PMID:15616584. http://dx.doi.org/10.1038/sj.emboj.7600509.
35. Irizarry RA, Ladd-Acosta C, Wen B, Wu Z, Montano C, Onyango P, et al. The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet 2009. 41:178-186. PMID:19151715. http://dx.doi.org/10.1038/ng.298.
36. Kandimalla R, van Tilborg AAG, Kompier LC, Stumpel DJPM, Stam RW, Bangma CH, et al. Genome-wide Analysis of CpG Island Methylation in Bladder Cancer Identified TBX2, TBX3, GATA2 and ZIC4 as pTa-Specific Prognostic Markers. Eur Urol 2012. 61:1245-1256. PMID:22284968. http://dx.doi.org/10.1016/j.eururo.2012.01.011.
37. Marsit CJ, Houseman EA, Christensen BC, Gagne L, Wrensch MR, Nelson HH, et al. Identification of methylated genes associated with aggressive bladder cancer. PLoS One 2010. 5:12334. PMID:20808801. http://dx.doi.org/10.1371/journal.pone.0012334.
38. Fackler MJ, Umbricht CB, Williams D, Argani P, Cruz LA, Merino VF, et al. Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence. Cancer Res 2011. 71:6195-6207. PMID:21825015. http://dx.doi.org/10.1158/0008-5472.CAN-11-1630.
39. Fiegl H, Windbichler G, Mueller-Holzner E, Goebel G, Lechner M, Jacobs IJ, et al. HOXA11 DNA methylation-a novel prognostic biomarker in ovarian cancer. Int J Cancer 2008. 123:725-729. PMID:18478570. http://dx.doi.org/10.1002/ijc.23563.
40. Strathdee G, Holyoake TL, Sim A, Parker A, Oscier DG, Melo JV, et al. Inactivation of HOXA genes by hypermethylation in myeloid and lymphoid malignancy is frequent and associated with poor prognosis. Clin Cancer Res 2007. 13:5048-5055. PMID:17785556. http://dx.doi.org/10.1158/1078-0432.CCR-07-0919.
41. Atkinson SP, Koch CM, Clelland GK, Willcox S, Fowler JC, Stewart R, et al. Epigenetic marking prepares the human HOXA cluster for activation during differentiation of pluripotent cells. Stem Cells 2008. 26:1174-1185. PMID:18292213. http://dx.doi.org/10.1634/stemcells.2007-0497.
42. Houseman EA, Christensen BC, Karagas MR, Wrensch MR, Nelson HH, Wiemels JL, et al. Copy number variation has little impact on bead-array-based measures of DNA methylation. Bioinformatics 2009. 25:1999-2005. PMID:19542153. http://dx.doi.org/10.1093/bioinformatics/btp364.
43. Troyanskaya O, Cantor M, Sherlock G, Brown P, Hastie T, Tibshirani R, et al. Missing value estimation methods for DNA microarrays. Bioinformatics 2001. 17:520-525. PMID:11395428. http://dx.doi.org/10.1093/bioinformatics/17.6.520.
44. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004. 3:3.
45. Venkatraman ES, Olshen AB. A faster circular binary segmentation algorithm for the analysis of array CGH data. Bioinformatics 2007. 23:657-663. PMID:17234643. http://dx.doi.org/10.1093/bioinformatics/btl646.
46. Staaf J, Jönsson G, Ringnér M, Vallon-Christersson J. Normalization of array-CGH data: influence of copy number imbalances. BMC Genomics 2007. 8:382. PMID:17953745. http://dx.doi.org/10.1186/1471-2164-8-382.
47. Bibikova M, Le J, Barnes B, Saedinia-Melnyk S, Zhou L, Shen R, et al. Genome-wide DNA methylation profiling using Infinium® assay. Epigenomics 2009. 1:177-200. PMID:22122642. http://dx.doi.org/10.2217/epi.09.14.
48. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. The Gene Ontology Consortium. Gene ontology: tool for the unification of biology. Nat Genet 2000. 25:25-29. PMID:10802651. http://dx.doi.org/10.1038/75556
49. Bailey TL, Boden M, Buske FA, Frith M, Grant CE, Clementi L, et al. MEME SUITE: tools for motif discovery and searching. Nucleic Acids Res 2009. 37:202-208. PMID:19458158. http://dx.doi.org/10.1093/nar/gkp335.
50. Veerla S, Ringnér M, Höglund M. Genome-wide transcription factor binding site/promoter databases for the analysis of gene sets and co-occurrence of transcription factor binding motifs. BMC Genomics 2010. 11:145. PMID:20193056. http://dx.doi.org/10.1186/1471-2164-11-145.